Monday, January 4, 2016
Rochester, N.Y.-based iCardiac Technologies, a provider of cardiac safety assessments, has voiced support of the official release of a regulatory revision enacted by the International Council for Harmonization (ICH) that defines and enables an alternative path to the conduct of a Thorough QT (TQT) study in clinical drug development.
The Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation has approved $7.5 million in funding for nine new projects between U.S. and Israeli companies. In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total value of all projects to $21 million.
The Pulse on Study Conduct by Elizabeth Weeks-Rowe
To provide an informed consent process that’s transparent and equitable is the most sacrosanct assurance of safety we can provide research patients.
Tetragenetics, an emerging biotechnology company engaged in the expression of ion channel drug targets, has announced a new partnership program for the discovery and development of therapeutic monoclonal antibodies (mAbs) directed against well-known ion channel drug targets implicated in a wide range of disease states—such as pain and autoimmune disorders.